We advised Akeso in the placement of new shares

Davis Polk advised Akeso, Inc. in its placement of 24,000,000 new shares, for an aggregate consideration of approximately HK$582 million. 

Davis Polk also advised the sole placing agent for Akeso, Inc.’s HK$1.19 billion share placement in February 2021, and the underwriters on Akeso, Inc.’s HK$2.44 billion IPO in April 2020.

Akeso, Inc. is a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of innovative antibody drugs that are affordable to patients worldwide. The company has established a comprehensive end-to-end drug development platform, ACE Platform, encompassing fully integrated drug discovery and development functions, including target validation, antibody drug discovery and development, CMC process development and GMP-compliant commercial scale manufacturing.

The Davis Polk team included partner Yang Chu and associate Michelle Chow. Members of the Davis Polk team are based in Hong Kong office.

Copy link to share post